https://www.businesswire.com/news/home/20250617760732/en/SunRock-Biopharma-and-Escugen-Forge-Alliance-to-Develop-First-in-Class-CCR9-Targeted-ADC
SunRock Biopharma and Escugen Forge Alliance to Develop First-in-Class CCR9-Targeted ADC
SunRock Biopharma and Escugen have joined forces in a strategic partnership to co-develop SRB123, a First-in-Class antibody-drug conjugate (ADC) targeting C-...